Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
Want to see MNPR full AI Analyst Report?
MNPR Stock Chart & Stats
$56.22
-$0.61(-2.42%)
At close: 4:00 PM EST
$56.22
-$0.61(-2.42%)
Day’s Range― - ―
52-Week Range$29.18 - $105.00
Previous CloseN/A
Volume23.12K
Average Volume (3M)168.32K
Market Cap
$400.40M
Enterprise Value$383.29M
Total Cash (Recent Filing)$137.49M
Total Debt (Recent Filing)$131.56K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 06, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding6,699,062
10 Day Avg. Volume122,205
30 Day Avg. Volume168,322
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-24.51
Forecast
1Y Price Target
$111.89Price Target Upside99.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical EfficacyRobust Phase 3 FoCus results showing superior neurologic improvement versus standard care, sustained benefits for ~3 years across long follow-up, and favorable safety strengthen the program's clinical and regulatory credibility, materially increasing the probability of eventual approval and long-term market impact.
Mechanistic Clinical ProofPeer‑reviewed Phase 2 data demonstrating meaningful, mechanistic reductions in copper balance and increased fecal excretion provide biological validation and reproducibility of effect. This strengthens differentiation versus current care and supports durable clinical positioning and payer/regulatory dialogue.
Commercial Leadership HireHiring a seasoned commercial executive signals a deliberate shift from development to commercialization readiness. Her track record building launches and commercialization infrastructure enhances the company's execution capability for market entry, reimbursement planning and long-term product adoption in rare disease markets.
Bears Say
No Revenue; Rising LossesThe company remains pre‑revenue with materially worsening net losses, meaning operational viability depends on future regulatory success and external funding. Persistent losses weaken return metrics and create structural execution risk until product revenues materialize or sustainable partnerships emerge.
Negative Cash Flow TrendConsistent negative operating and free cash flow, and a pronounced step‑up in cash outflows recently, elevate refinancing risk and constrain runway. This undermines the firm's ability to independently fund late‑stage activities and commercialization without dilutive capital or strategic partnerships.
Financing Dependence & Equity ShiftsWhile leverage is low, large equity base shifts imply frequent or sizable equity financings. Reliance on dilutionary capital raises governance and shareholder dilution risk, potentially limiting strategic flexibility and investor returns during the multi‑year path to commercialization.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $29.18 and its highest was $105.00 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $400.40M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on May 14, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.213.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.6.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,699,062 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went down -0.732%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$111.89 (99.02% Upside)
$111.89 (99.02% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 152.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
76.72%
12-Months-Change
Fundamentals
Return on Equity
-12.84%
Trailing 12-Months
Asset Growth
150.49%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Validive, a specialized clonidine hydrochloride mucobuccal tablet, is currently undergoing Phase 2b/3 clinical trials. This therapy aims to prevent severe oral mucositis, a debilitating side effect of chemoradiotherapy, in patients suffering from oropharyngeal cancer. The company's pipeline also includes Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for advanced soft tissue sarcoma. Furthermore, Monopar is developing MNPR-101, an antibody engineered to target the urokinase plasminogen activator receptor (uPAR) for various cancer indications. A radioimmunotherapeutic variant of MNPR-101, named MNPR-101 RIT, is being explored for its potential in both cancer therapy and the treatment of severe COVID-19. Another promising compound, MNPR-202, an analog of camsirubicin, is being developed to potentially address cancers that have developed resistance to doxorubicin and camsirubicin. Monopar Therapeutics Inc. maintains strategic partnerships, including one with the Grupo Español de Investigación en Sarcomas (GEIS) for the advancement of camsirubicin in patients with advanced soft tissue sarcoma. They also collaborate with NorthStar Medical Radioisotopes, LLC on the development of radio-immunotherapeutics targeting severe COVID-19, and with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related compounds across different cancer types. The company was established in 2014 and its corporate headquarters are situated in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$111.89
▲(99.02% Upside)
Technical Analysis
Cardiff Oncology
―
Vanda
―
Verastem
―
Mereo Biopharma Group Plc
―
Silence Therapeutics
―
Ownership Overview
17.96% Insiders
6.67% Mutual Funds
45.93% Other Institutional Investors
22.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---